This website is for informational purposes only and does not constitute medical advice. Read disclaimer
Retatrutide
Based primarily on community reports and observational data
A triple-acting agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, representing the next evolution in incretin-based obesity treatment with the highest weight loss observed in clinical trials to date.
Overview
Retatrutide is a novel triple hormone receptor agonist developed by Eli Lilly that simultaneously activates three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. This triple mechanism represents an evolution beyond the dual GIP/GLP-1 agonism of tirzepatide, adding glucagon receptor activation to further enhance metabolic effects, particularly fat burning and energy expenditure.
The addition of glucagon receptor agonism is a bold pharmacological strategy. Glucagon has historically been associated with raising blood sugar and was considered counterproductive in diabetes treatment. However, at the doses and in the context of combined GIP/GLP-1 activation, glucagon receptor stimulation adds significant energy expenditure and lipolytic effects. It may also contribute to reduced food intake and improved liver fat metabolism. The balance of these three hormone signals appears to produce weight loss exceeding that of any previous pharmacological approach.
Phase 2 clinical trial results for retatrutide generated enormous excitement. In the study published in the New England Journal of Medicine in 2023, the highest dose group (12 mg weekly) achieved mean weight loss of 24.2% at 48 weeks — the highest weight loss ever reported for a pharmacological agent in a clinical trial. Nearly 100% of participants in the highest dose group lost at least 5% of their body weight, and over 25% lost more than 30% of their body weight.
Phase 3 trials are ongoing, and if results confirm the phase 2 findings, retatrutide could become the most effective anti-obesity medication ever developed. Beyond weight loss, the phase 2 trial showed significant improvements in glycemic control, blood pressure, and lipid parameters. Research is also exploring retatrutide for non-alcoholic steatohepatitis (NASH) and other metabolic conditions. The drug represents the cutting edge of incretin-based therapy and the pharmaceutical industry's aggressive pursuit of more effective obesity treatments.
## Key PubMed References
[1] Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023;389(6):514-526. PMID: 37385337
[2] Rosenstock J, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial." Lancet. 2023;402(10401):529-544. PMID: 37385280
[3] Coskun T, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss." Cell Metab. 2022;34(9):1234-1247.e9. PMID: 36070752
[4] Urva S, et al. "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial." Lancet. 2022;400(10366):1869-1881. PMID: 36354040
[5] Finan B, et al. "A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents." Nat Med. 2015;21(1):27-36. PMID: 25485909
